On September 25, Johnson & Johnson (NYSE:JNJ) announced top-line findings from its Phase 4 STAR study evaluating Tremfya (guselkumab) in biologic-naïve adults with active psoriatic arthritis (PsA) and axial involvement. Tremfya met primary and secondary endpoints, demonstrating improvements in axial symptoms alongside MRI-confirmed reductions in joint inflammation. As the first randomized, placebo-controlled study to prospectively evaluate an IL-23 inhibitor using objective MRI assessments, these findings reinforce Tremfya’s clinical profile and bolster J&J’s core immunology franchise.
You May Also Want To Read: Jim Cramer Picks J&J (JNJ) Over Eli Lilly (LLY) and Pfizer (PFE) Among These Healthcare Stocks
Bull Case: High Margins, Robust Pipeline, and Strong Cash Flow
The STAR study success directly supports J&J’s strategy to expand its key immunology growth drivers as legacy products face pressure. In Q2 2026, J&J reported operational sales growth of 5.6% to $25.3 billion, driven by 6.8% operational growth in Innovative Medicine, where Tremfya serves as a core engine alongside Oncology blockbusters DARZALEX and CARVYKTI. Strong execution allowed management to raise full-year 2026 sales guidance to $101.1 billion at the midpoint (7.3% growth) and adjusted operational EPS guidance to $11.58.
Tremfya’s label expansion momentum reinforces J&J’s premium margins and durable cash generation, which produced approximately $8.7 billion in free cash flow year-to-date through Q2. This strong cash position provides the balance sheet flexibility needed to fund ongoing pipeline development and strategic M&A without taking on balance sheet strain.
Bear Case: Stelara Erosion, Product Expiries, and Operational Pressures
Despite pipeline milestones, J&J faces revenue replacement risks from biologic loss of exclusivity. Q2 2026 results revealed an approximate 760-basis-point operational growth drag from declining Stelara sales due to biosimilar entry, illustrating how quickly legacy biologic revenues erode. While Tremfya’s positive STAR trial data expands its addressable population, market uptake must scale rapidly to replace Stelara’s multi-billion-dollar cash flow stream.
Furthermore, MedTech growth showed moderation at 3.6% operational growth in Q2 2026, highlighting sensitivity to elective procedure volumes and regional demand fluctuations. Ongoing litigation reserves and restructuring charges also present near-term headwinds, which could weigh on overall return on capital if revenue growth from new indications lags expectations.
Don’t Miss: Johnson & Johnson (JNJ) Taps Sail Biomedicines in Bid for CAR-T Edge Over Bristol Myers Squibb
Conclusion
The STAR study trial victory provides strong validation for Tremfya, offering J&J a clear clinical differentiator in axial PsA. With Q2 2026 revenues surpassing $25 billion and guidance raised past $100 billion, J&J demonstrates that its commercial execution can absorb legacy product declines. While biosimilar erosion and litigation overhangs remain headwinds, continuous pipeline advances like Tremfya ensure J&J remains well-positioned to sustain high-margin growth.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
Hedge Fund Resource Center